Chaim Lebovits joined BrainStorm in July 2007 as President and has served as Chief Executive Officer since September 2015. He has been instrumental in shaping development of the NurOwn® technology platform from early preclinical stages to the current phase 3 clinical program in the United States. In the last two years, Mr. Lebovits has played a pivotal role in bringing additional strength and depth to the BrainStorm executive team, recruiting a number of biotech executives with critical clinical development and path-to-market experience to support the phase 3 development and regulatory filing of autologous MSC-NTF cells in ALS and MS.

In addition to his biotech experience, Mr. Lebovits is a senior executive on the board of a number of public and private companies involved in natural resource exploration projects around the world.